Free Trial
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
$8.61
$8.58
$3.55
▼
$8.61
$391.24M0.54637,200 shsN/A
Ten Starter Stocks For Beginners to Buy Now Cover
Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
0.00%0.00%0.00%0.00%+95.24%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
$8.61
$8.58
$3.55
▼
$8.61
$391.24M0.54637,200 shsN/A
Ten Starter Stocks For Beginners to Buy Now Cover
Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
0.00%0.00%0.00%0.00%+95.24%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
2.00
Hold$9.5110.50% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
$87.68M4.46N/AN/A$2.05 per share4.20
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
-$29.67M-$0.50N/AN/AN/A-26.03%-24.60%-18.89%N/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
N/A
4.00
3.58

Institutional Ownership

CompanyInstitutional Ownership
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
70.85%

Insider Ownership

CompanyInsider Ownership
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
19.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
15045.44 million36.49 millionOptionable

Recent News About These Companies

Y-Mabs Therapeutics Completes Merger with Perseus BidCo
September 16, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/y-mabs-therapeutics-completes-merger-with-perseus-bidco?utm_source=marketbeat.com&utm_medium=referral
Y-Mabs Therapeutics’ Phase 2 Trial: A Potential Breakthrough for Neuroblastoma Treatment
September 7, 2025  |  msn.comhttps://www.msn.com/en-us/health/diseases-and-conditions/y-mabs-therapeutics-phase-2-trial-a-potential-breakthrough-for-neuroblastoma-treatment/ar-AA1M46dw
Y-mAbs Therapeutics, Inc. (YMAB) Now Trades Above Golden Cross: Time to Buy?
September 1, 2025  |  zacks.comhttps://www.zacks.com/stock/news/2745527/y-mabs-therapeutics-inc-ymab-now-trades-above-golden-cross-time-to-buy?cid=cs-stocknewsapi-ft-tale_of_the_tape|golden_crossover-2745527
Y-MABS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB
August 19, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/08/20/3136088/6713/en/y-mabs-therapeutics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-y-mabs-therapeutic.html
Acquisition Deal Triggers Weekly Surge for Y-mAbs Therapeutics Stock
August 13, 2025  |  insidermonkey.comhttps://www.insidermonkey.com/blog/acquisition-deal-triggers-weekly-surge-for-y-mabs-therapeutics-stock-1589285/
A Look Ahead: Y-mAbs Therapeutics's Earnings Forecast
August 9, 2025  |  benzinga.comhttps://www.benzinga.com/insights/earnings/25/08/46970486/a-look-ahead-y-mabs-therapeuticss-earnings-forecast
Y-mAbs (YMAB) Q2 Revenue Falls 14%
August 9, 2025  |  aol.comA
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates
August 8, 2025  |  zacks.comhttps://www.zacks.com/stock/news/2683340/y-mabs-therapeutics-inc-ymab-reports-q2-loss-tops-revenue-estimates?cid=cs-stocknewsapi-ft-tale_of_the_tape|yseop_template_4-2683340
Shareholder Alert: The Ademi Firm Investigates Whether Y-mAbs Therapeutics Inc. is Obtaining a Fair Price for its Public Shareholders
August 8, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250808933548/en/shareholder-alert-the-ademi-firm-investigates-whether-y-mabs-therapeutics-inc.-is-obtaining-a-fair-price-for-its-public-shareholders/
Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments
August 8, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/08/08/3130042/0/en/y-mabs-reports-second-quarter-2025-financial-results-and-recent-corporate-developments.html
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB)
August 7, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-y-mabs-therapeutics-inc-nasdaq-ymab-302524869.html
Y-MABS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB
August 7, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250807034703/en/y-mabs-therapeutics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-y-mabs-therapeutics-inc.---ymab/
Y-mAbs Therapeutics, Inc. to Report Q2 2025 Financial Results on August 8, 2025, forgoing Earnings Call
August 7, 2025  |  quiverquant.comQ
Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025
August 7, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/08/07/3129120/0/en/y-mabs-to-announce-second-quarter-2025-financial-and-operating-results-on-august-8-2025.html
HC Wainwright & Co. Downgrades Y-mAbs Therapeutics (YMAB)
August 7, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/hc-wainwright-co-downgrades-y-mabs-therapeutics-ymab/ar-AA1K3Nlv
SERB bets on rare cancer drug in $412 million deal for Y-mAbs
August 6, 2025  |  thepharmaletter.comT
Jones Trading Downgrades Y-mAbs Therapeutics (YMAB)
August 6, 2025  |  msn.comhttps://www.msn.com/en-us/money/markets/jones-trading-downgrades-y-mabs-therapeutics-ymab/ar-AA1K27jE
YmAbs Therapeutics (YMAB) Surges 103.3%: Is This an Indication of Further Gains?
August 6, 2025  |  zacks.comhttps://www.zacks.com/stock/news/2673237/ymabs-therapeutics-ymab-surges-103-3-is-this-an-indication-of-further-gains?cid=cs-stocknewsapi-ft-tale_of_the_tape|daily_price_change_5%-2673237
Shareholder Alert: The Ademi Firm investigates whether Y-mAbs Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
August 5, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/shareholder-alert-the-ademi-firm-investigates-whether-y-mabs-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders-302522065.html
Y-mAbs stock soars after SERB Pharmaceuticals announces acquisition
August 5, 2025  |  investing.comhttps://www.investing.com/news/stock-market-news/ymabs-stock-soars-after-serb-pharmaceuticals-announces-acquisition-93CH-4170530
Y-mAbs Therapeutics stock logo

Y-mAbs Therapeutics NASDAQ:YMAB

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas